The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TAOX | +178.68% | N/A | N/A | -91% |
| S&P | +14.18% | +88.25% | +13.47% | +85% |
Synaptogenix, Inc. is a biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.
No news articles found for Tao Synergies.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.20M | 0.0% |
| Gross Profit | $0.20M | 12093.4% |
| Gross Margin | 99.61% | 0.0% |
| Market Cap | $22.84M | 475.5% |
| Market Cap / Employee | $3.81M | 0.0% |
| Employees | 6 | -25.0% |
| Net Income | -$3.92M | 31.7% |
| EBITDA | -$1.39M | -2.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.45M | -92.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -129.18% | -99.4% |
| Return On Invested Capital | -108.89% | -26.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.19M | -15.9% |
| Operating Free Cash Flow | -$1.19M | -15.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.37 | 0.56 | 2.11 | 0.95 | 372.06% |
| Price to Sales | 3101.17 | 80.55 | - | ||
| Price to Tangible Book Value | 0.37 | 0.56 | 2.11 | 0.95 | 372.06% |
| Enterprise Value to EBITDA | 5.95 | 10.73 | 2.16 | -0.34 | -102.57% |
| Return on Equity | -84.5% | -89.5% | -154.6% | -180.5% | 334.31% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
